mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say Ars TechnicaModerna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 150% CNBCA New mRNA Vaccine Could Prevent Melanoma From Returning The New York TimesModerna's 160% Surge Burns Shorts in ‘Painful' $5 Billion Loss Bloomberg
|
